Wedbush Reiterates Outperform on Immunic, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Negative 82.4%

Neg 82.4% Neu 0% Pos 0%

Wedbush analyst Martin Fan reiterates Immunic (NASDAQ:IMUX) with a Outperform and maintains $45 price target.

Comments

No comments yet. Be the first!